International Conference On OpioidsInternational Conference On Opioids
  • Home
  • Presentations
  • Posters
  • Info
    • ——————————
      • Call For Presentations, Posters, etc
      • CME Information
      • Sponsorship & Exhibits
    • ——————————
      • Opioid Safety Tips Project
      • Press & Media
        • Speakers
      • Lodging and hotels
    • ——————————
      • Conference Information
      • Terms and conditions
      • Tickets
      • Contact Us
    • ——————————
      • Conference Committee
      • Educational Support
      • Satellite Symposia
  • Register Now to Watch
  • Login
  • Home
  • Presentations
  • Posters
  • Info
    • ——————————
      • Call For Presentations, Posters, etc
      • CME Information
      • Sponsorship & Exhibits
    • ——————————
      • Opioid Safety Tips Project
      • Press & Media
        • Speakers
      • Lodging and hotels
    • ——————————
      • Conference Information
      • Terms and conditions
      • Tickets
      • Contact Us
    • ——————————
      • Conference Committee
      • Educational Support
      • Satellite Symposia
  • Register Now to Watch
  • Login

Posters

icoo.20.pp.0030 Rzetelny and Marcus 2020 Poster UDT Relapses Slides
11/172020

Relapses during addiction treatment found after a change in urine drug testing methodologies

Posters

Relapses during addiction treatment found after a change in urine drug testing methodologies

Introduction: Definitive urine drug testing (UDT) may provide a more complete picture of a patient’s drug-taking behaviors than presumptive UDT. Definitive UDT involves mass spectrometry, either LC-MS/MS or GCMS, and may not require a screen. In contrast, presumptive UDT, sometimes referred to as screen-first, involves immunoassay, such as point-of-care cups, and chemical analyzers, and may be followed by confirmation of positive results. Substance-use counselors have previously reported that switching from presumptive to definitive UDT helped identify relapses and impacted the quality of counseling, treatment planning, and patient outcomes. However, an objective assessment of new relapses potentially identified when switching UDT methodologies had yet to be undertaken.

Presented by:

Adam Rzetelny,2 PhD and Adrienne Marcus,3 PhD

2Collegium Pharmaceuticals, Stoughton MA; 3Lexington Recovery, Katonah NY

Video Poster:

https://opioidconference.org/wp-content/uploads/2020/11/icoo.20.pp_.0030-Rzetelny-and-Marcus-2020-Poster-UDT-Relapses-Slides-720P.mp4

Poster PDF: icoo.20.pp.0030 ICOO Poster UDT reveals SUD relapses AR sept 2020 v2

Poster Presentation Slide Handouts: icoo.20.pp.0030 Rzetelny and Marcus 2020 Poster UDT Relapses Slide Handout

Read more
icoo.20.pp.0051_ICOO Poster_Cioe_96DPI
10/292020

A Systematic Review of Patient and Provider Perspectives of Medications for Treatment of Opioid Use Disorder

Posters

A Systematic Review of Patient and Provider Perspectives of Medications for Treatment of Opioid Use Disorder

This systematic review focuses on published manuscripts that have assessed the preferences and attitudes of MOUD by providers and/or patients.

The aim of this systematic review is to disentangle the opinions about these medications to understand how patient and provider beliefs may impact choice of MOUD and the efficacy of addiction treatment.

Presented by: Katharine Cioe, BS1,Breanne E. Biondi, MPH2, Rebecca Easly, BA1, Amanda Simard, BS1,  Xiao Zheng3, Sandra A. Springer, MD2,4

1Frank H. Netter School of Medicine, 2Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, 3Yale University, 4Center for Interdisciplinary Research on AIDS, Yale University School of Public Health

Poster in PDF format: icoo.20.pp.0051_ICOO Poster_Cioe

Read more
icoo.20.pp.0056_Possanza_MS2986_Partnership_ConferencePoster_ICOO2020 (002)150DPI
10/292020

Safe Practice Recommendations Through Technology for Safer Opioid Prescribing Using Measures and Clinical Decision Support

Posters

Safe Practice Recommendations Through Technology for Safer Opioid Prescribing Using Measures and Clinical Decision Support

The United States remains in the midst of a deadly opioid use epidemic. Contributing to this crisis, between 3-10% of opioid-naïve* patients who are prescribed opioids progress on to chronic opioid use, with the associated increased risk for overuse or dependence. Outside stresses only exacerbate the potential for these issues. Although it is unknown exactly how clinicians’ opioid prescribing habits are related to rates of subsequent misuse, a few studies suggest specific parameters for how long or at what dosage can be prescribed for opioid-naïve patients without inadvertently promoting long-term use.

Presented by: Patricia Giuffrida, MSN, RN, CPHIMS, Senior Patient Safety and Health IT Safety Analyst, ECRI; Shari Medina, MD, Harris Healthcare, Vice Chair of the EHRA Executive Committee, EHRA Patient Safety Workgroup, Robert Giannini, Patient Safety Analyst and Consultant, ECRI, Lorraine Possanza, DPM, JD, MBE, Program Director, Partnership for Health It Patient Safety, ECRI; contact HIT@ecri.org

Audio Poster:

https://opioidconference.org/wp-content/uploads/2020/10/icoo.20.pp_.0056-Edited-v3-HIT_10242018_Intro_Final_01-1.mp3

Poster in PDF format: icoo.20.pp.0056_Possanza_MS2986_Partnership_ConferencePoster_ICOO2020 (002)

Read more
icoo.20.pp.0086 Screen Shot
10/292020

An Evaluation of Post-Operative Opioid Prescribing Patterns Compared to Recent Procedure-Specific Guideline Recommendations

Posters

An Evaluation of Post-Operative Opioid Prescribing Patterns Compared to Recent Procedure-Specific Guideline Recommendations

Eskenazi Health compared prescribing after common procedures to published recommendations. This presentation will review how prescribing habits were evaluated and discuss how to improve prescribing to align with recommendations. This presentation will introduce a method that can be reproduced at other institutions looking to improve post-procedure prescribing habits and metrics.

Presented by: Michelle E. Busch, PharmD, BCPS and Todd A. Walroth, PharmD, BCPS, BCCCP, FCCM
Eskenazi Health, Indianapolis, IN

Poster PDF: icoo.20.pp.0086 ICOO Poster_Opioid Prescribing MUE

 

Read more
icoo.20.pp.0081 Screen Shot
10/292020

Taking a New Approach to Opioid Stewardship: Implementation of an Opioid Stewardship Pharmacist and an Interdisciplinary Oversight Committee

Posters

Taking a New Approach to Opioid Stewardship: Implementation of an Opioid Stewardship Pharmacist and an Interdisciplinary Oversight Committee

An opioid stewardship pharmacist and pain oversight committee encourages collaboration, allows for prioritization of projects, and aims to overcome barriers. This presentation will focus on how Eskenazi Health’s stewardship program and oversight committee were developed and how to convert goals into actionable projects, with sharing of results and data.

Presented by: Michelle E. Busch, PharmD, BCPS and Todd A. Walroth, PharmD, BCPS, BCCCP, FCCM
Eskenazi Health, Indianapolis, IN

Poster PDF: icoo.20.pp.0081 ICOO Poster_Stewardship

 

Read more
icoo.20.pp.0016_Screen Shot
10/292020

Can Unmanned Aerial Vehicles Supplement Services Provided by Traditional First Responders?

Posters

Can Unmanned Aerial Vehicles Supplement Services Provided by Traditional First Responders?

The investigators look at the use of DRONES to deliver life saving naloxone and analyze response times compared to traditional EMS/Fire/Police response.
The investigators have also expanded their work to include surveillance, communication and screening for COVID-19 patients.

Presented by: Matthew R. Tukel BA, Connor A. Tukel BA, Robert J. Weinbaum BS, Phillip D. Levy MD, MPH, Robert Dunne MD, FAEMS, FACEP.
Wayne State University School of Medicine, Department of Emergency Medicine

Video Poster:

https://opioidconference.org/wp-content/uploads/2020/09/icoo.20.pp_.0016_Tukel_ICO-Video.mp4

Poster PDF: icoo.20.pp.0016 ICO_2020_Poster (FINAL)

Read more
icoo.20.pp.0011_TuanW_ICOO_2020_Poster_20200821_1280x960
08/212020

Assessing Opioid Dosage Using Electronic Health Records’ Prescription Data

Posters

Assessing Opioid Dosage Using Electronic Health Records’ Prescription Data

 

Many patients with chronic pain rely on long-term opioid therapy, which can lead to dose-dependent harms, including opioid addiction or overdose death. Tracking opioid dose from electronic health record (EHR) data is often challenging, with variability across health systems. Standardized approach to quantify daily morphine milligram equivalent (MME) dose could help health systems and clinicians better monitor opioid prescribing, improving chronic pain care and patient safety.

Presented by: Wen-Jan Tuan, DHA MS MPH1, Nalini Sehgal, MD1, June Dahl, PhD1, Aleksandra E. Zgierska, MD PhD DFASAM2

1 University of Wisconsin School of Medicine and Public Health, Madison, WI 2 Penn State College of Medicine, Hershey, PA

Poster PDF – icoo.20.pp.0011_TuanW_ICOO_2020_Poster_20200821

Read more
ICOO Resp Drive Poster_Final_150DPI
08/172020

A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone on Respiratory Drive

Posters 1

A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride on Respiratory Drive

Presented by:

Lynn Webster, MD1; Jacqueline Cater, PhD1; Thomas Smith, MD

Video Poster:

https://opioidconference.org/wp-content/uploads/2020/08/icoo.20.pp_.0006_ICOO_Resp_Drive_Slides_FINAL-14Aug2020.mp4

Poster in PDF format:

icoo.20.pp.0008_ICOO Resp Drive Poster_Final

Read more
icoo.20.pp.0002_WV Project ECHO ICOO Poster Final
07/082020

WV Project ECHO Chronic Pain: Maximizing the Impact of Education & Training in the Opioid Crisis

Posters 1

WV Project ECHO Chronic Pain:
Maximizing the Impact of Education & Training in the Opioid Crisis

 

The ECHO model is a dynamic continuing education program due to its case-based learning and mentorship design. Community providers get recommendations on actual patients that are presented during the sessions and those recommendations can then be implemented into the patient’s care in real-time.

Presented by:

Charles Ponte, BS, PharmD, BC-ADM, BCPS, CDE, CPE, FAADE, FAPhA, FASHP, FCCP, FNAP; Jay Mason, MPA; Kayetlyn Edinger, MPA; Mithra Mohtasham, MPA; Mark Garofoli, PharmD, MBA, BCGP, CPE

Video Poster:

https://opioidconference.org/wp-content/uploads/2020/08/icoo.20.pp_.0001_ICOO-Poster-Presentation-WV-Project-ECHO.mp4

Poster PDF: icoo.20.pp.0001 WV Project ECHO ICOO Poster Final

Read more
Search
Latest Presentations
  • Clinical Pearls of Pharmacogenomics December 23, 2020
  • Relapses during addiction treatment found after a change in urine drug testing methodologies November 17, 2020
  • Preliminary Results from a Post-Overdose Outreach & Emergency Department-Initiated Opioid Initiative November 12, 2020
  • Opioid Induced Constipation in Chronic Pain November 9, 2020
Categories
  • Posters
  • Presentations

The 2020 International Conference on Opioids (ICOO 2020) has assembled the best and brightest minds in opioid analgesics who will explore the challenges of using opioids to treat pain.

The International Conference On Opioids is dedicated to presenting the latest research and practice for managing patients on opioid therapies. The conference addresses all aspects of opioids in medicine and the public health.

INFORMATION
  • Terms and conditions
  • Privacy Statement
NEWSLETTER


    Contact Us
    info@opioidconference.org
    Copyright 2020 Weston Medical Publishing, LLC - All Rights Reserved | Website Design By - T3kniq
    This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    Privacy Statement


    Privacy and User Data Policy

    GDPR Update:

    The data collected from registered and non-registered users of this journal falls within the scope of the standard functioning of peer-reviewed journals. It includes information that makes communication possible for the editorial process; it is used to informs readers about the authorship and editing of content; it enables collecting aggregated data on readership behaviors, as well as tracking geopolitical and social elements of scholarly communication.

    This journal’s editorial team uses this data to guide its work in publishing and improving this journal. Data that will assist in developing this publishing platform may be shared with its developer Public Knowledge Project in an anonymized and aggregated form, with appropriate exceptions such as article metrics. The data will not be sold by this journal or PKP nor will it be used for purposes other than those stated here. The authors published in this journal are responsible for the human subject data that figures in the research reported here.

    Those involved in editing this journal seek to be compliant with industry standards for data privacy, including the European Union’s General Data Protection Regulation (GDPR) provision for “data subject rights” that include (a) breach notification; (b) right of access; (c) the right to be forgotten; (d) data portability; and (e) privacy by design. The GDPR also allows for the recognition of “the public interest in the availability of the data,” which has a particular saliency for those involved in maintaining, with the greatest integrity possible, the public record of scholarly publishing.

    Requests per item (a) through (e) above should be sent to the journal's mailbox, jom(at)pnpco.com

    The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

    What Data does this Website Process?

    The system, based the PKP Open Journal System applications, process personal data as a fundamental part of their operations. Most data is only provided by consent, ie. through manual user registration, though some visitation data (eg. cookies, usage logs) may also be recorded.

    User Registration Data

    When a visitor creates a user account in a PKP application, the following personal information is processed and stored (with some minor variation between OMP and OJS, and from version to version):

    ●   Salutation

    ●   First name*

    ●   Middle name

    ●   Last name*

    ●   Suffix

    ●   Username

    ●   Gender

    ●   Password (encrypted)

    ●   Email address*

    ●   ORCiD ID

    ●   Website

    ●   Mailing Address

    ●   Country

    ●   Phone

    ●   Fax

    ●   Affiliation

    ●   Biography

    ●   Registration date

    ●   Last login date

    ●   Locales

    ●   Reviewing interests

    ●   Role registrations (author, reader, and/or reviewer)

    Only the username, first name, last name, email and password fields are required.

    Storage

    This information is stored in the application database. Only the user password

    is encrypted.

    Availability and Access

    This information is available to the user via their User Profile (and, with the exception of the username and dates, can be edited). System administrators, journal managers, and editors can also access and edit this data (except the username and dates) via the application back end. The data can be downloaded by journal managers in XML format. The data is not otherwise publicly available.

    Erasure

    This data can be erased by the journal manager using the Merge Users tool, without affecting any editorial records. The erasure is subject to the considerations raised in the section “Scholarly Publishing, Data Privacy, and the Public Interest”, above.

    Contributor Metadata Information

    When a manuscript is submitted to a PKP application, contributor information is included. Contributors can be authors, translators, volume editors, and so on. This information is stored as submission metadata and is provided as part of any published manuscript record. The following contributor information is collected:

    ●   Salutation

    ●   First name*

    ●   Middle name

    ●   Last name*

    ●   Email address*

    ●   Suffix

    ●   ORCiD ID

    ●   Website

    ●   Country*

    ●   Affiliation

    ●   Biography

    Only the first name, last name, email address and country fields are required.

    Storage

    This information is stored in the application database.

    Data Transfer

    We do not sell or transfer to third parties user information from this system.

    General Visitor Information

    PKP applications also collect general visitor usage data, including:

    ● Cookie information, to manage session history. Cookies are required to maintain a login session in PKP applications.

    ● Optionally, detailed usage log data, including: IP address; pages visited; date visited; and browser information, in application log files, as part of the Usage Statistics plugin. An anonymization option is available to privatize this information.

    ● Optionally, country, region and city information, in the metrics database. This data collection requires additional setup and is not enabled by default.

    Other data may be tracked, either on the server or via third parties:

    ● Script loads from CDN servers;

    ● IP address information (including date, browser, etc.) in web server logs (separate from application log files as part of the Usage Statistics plugin).

    Detailed instructions in limiting the amount of data you collect, and providing consent for the data you collect, can be found below.

    Storage

    ● Cookies: A cookie (usually titled “OJSSID” or “OMPSID”) is created when first visiting a PKP application and is stored on the visitor’s computer. It is only used to store a session ID, and to facilitate logins. (If the visitor blocks cookies, OJS will still work properly, though they will not be able to log in.)

    ● Usage Statistics log files: As part of the usage statistics framework and plugin, OJS may store detailed application log files in the submission files directory (configured as the files_dir parameter in the OJS config.inc.php file), in a “usageStats” directory.

    ● Geographical data: Filtered usage data, including possibly geographic data, is also stored in the OJS database, in a “metrics” table.

    Availability and Access

    ● Cookies: These are available via the visitor’s browser settings.

    ● Usage Statistics log files: Only individuals with server file access can access application log files.

    ● Geographical data: Journal Managers can access filtered usage data by using the OJS usage report plugins.

    Erasure

    ● Cookies: These can be deleted via the visitor browser.

    ● Usage Statistics log files: These can be erased by system administrators with file access.

    ● Geographical data: This can only be erased by deleting records from the database directly, which also typically requires system administrator access.

    Portions of this privacy statement are copyright by Simon Fraiser University Licensed wth CC4.0-BY.
    Necessary
    Always Enabled

    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

    Non-necessary

    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.